Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECCO 2017 | Testing novel biomarkers for treatment

Keith Kerr • 27 Jan 2017
ECCO 2017

Keith Kerr, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, Scotland, discusses testing novel biomarkers for treatment at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He explains that it is the availability of drugs that drives the testing of new biomarkers. However, biomarkers can sometimes take a long time to validate. This can lead to biomarker testing techniques being developed before the drugs have been approved. The disadvantage of doing this, however, is not knowing whether the drug will pass its Phase III trials and be approved.

More from Keith Kerr

2:55
Challenges of biomarker testing in the UK
Keith Kerr • 26 Apr 2023
3:32
Biomarker testing for ADCs
Keith Kerr • 27 Apr 2023
2:16
Pathology training in the molecular era
Keith Kerr • 24 Jan 2019
2:14
Pathology practice, an ever-changing field as more biomarkers emerge
Keith Kerr • 24 Jan 2019
The content of VJOncology is intended for healthcare professionals